Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data was obtained, however, which clearly indicated that the antiviral potency of 9-β-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.
|Original language||English (US)|
|Number of pages||6|
|Journal||Antimicrobial Agents and Chemotherapy|
|State||Published - 1980|
ASJC Scopus subject areas
- Pharmacology (medical)